Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA1) antagonists
Authors:
Open Access
- 1 March 2022
- journal article
- research article
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 438, 115846
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Pulmonary fibrosis: patterns and perpetratorsJournal of Clinical Investigation, 2012
- The Lysophosphatidic Acid Receptor LPA1 Promotes Epithelial Cell Apoptosis after Lung InjuryAmerican Journal of Respiratory Cell and Molecular Biology, 2012
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Investigational approaches to therapies for idiopathic pulmonary fibrosisExpert Opinion on Investigational Drugs, 2010
- A novel, orally active LPA 1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin modelBritish Journal of Pharmacology, 2010
- Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and RegulationPharmacological Reviews, 2010
- Idiopathic pulmonary fibrosisOrphanet Journal of Rare Diseases, 2008
- The Effect of Drugs on Bile Flow and CompositionDrugs, 1986
- Bile acid-induced liver toxicity: Relation to the hydrophobic-hydrophilic balance of bile acidsMedical Hypotheses, 1986